LAPTM5 –CD40 Crosstalk in Glioblastoma Invasion and Temozolomide Resistance

Conclusion: We conclude that LAPTM5 conveyed tumor suppression and temozolomide sensitation in CD40-positive glioblastoma through the inhibition of CD40-mediated NFκB activation. Hence, LAPTM5 may provide a potential biomarker for sensitivity to temozolomide in CD40-positive glioblastoma.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research